$40.59
1.30% yesterday
Nasdaq, Dec 03, 10:00 pm CET
ISIN
BMG5269C1010
Symbol
KNSA

Kiniksa Pharmaceuticals Ltd. Class A Stock price

$40.59
+3.12 8.33% 1M
+11.48 39.44% 6M
+20.81 105.21% YTD
+19.42 91.73% 1Y
+24.86 158.04% 3Y
+21.88 116.94% 5Y
+21.12 108.47% 10Y
+21.12 108.47% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+0.52 1.30%
ISIN
BMG5269C1010
Symbol
KNSA
Industry

Key metrics

Basic
Market capitalization
$3.1b
Enterprise Value
$2.7b
Net debt
positive
Cash
$352.1m
Shares outstanding
75.4m
Valuation (TTM | estimate)
P/E
90.2 | 38.4
P/S
5.1 | 4.5
EV/Sales
4.6 | 4.0
EV/FCF
26.8
P/B
5.8
Financial Health
Equity Ratio
75.5%
Return on Equity
-9.9%
ROCE
6.5%
ROIC
8.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$598.0m | $688.3m
EBITDA
$39.6m | $112.9m
EBIT
$38.2m | $97.7m
Net Income
$35.9m | $79.8m
Free Cash Flow
$101.7m
Growth (TTM | estimate)
Revenue
55.7% | 62.6%
EBITDA
262.5% | 357.0%
EBIT
245.4% | 314.3%
Net Income
496.0% | 284.8%
Free Cash Flow
816.5%
Margin (TTM | estimate)
Gross
87.5%
EBITDA
6.6% | 16.4%
EBIT
6.4%
Net
6.0% | 11.6%
Free Cash Flow
17.0%
More
EPS
$0.5
FCF per Share
$1.3
Short interest
6.9%
Employees
315
Rev per Employee
$1.3m
Show more

Is Kiniksa Pharmaceuticals Ltd. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Kiniksa Pharmaceuticals Ltd. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

Buy
92%
Hold
8%

Financial data from Kiniksa Pharmaceuticals Ltd. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
598 598
56% 56%
100%
- Direct Costs 75 75
42% 42%
12%
523 523
58% 58%
88%
- Selling and Administrative Expenses 180 180
10% 10%
30%
- Research and Development Expense 97 97
1% 1%
16%
40 40
262% 262%
7%
- Depreciation and Amortization 1.49 1.49
19% 19%
0%
EBIT (Operating Income) EBIT 38 38
245% 245%
6%
Net Profit 36 36
496% 496%
6%

In millions USD.

Don't miss a Thing! We will send you all news about Kiniksa Pharmaceuticals Ltd. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kiniksa Pharmaceuticals Ltd. Class A Stock News

Neutral
GlobeNewsWire
22 days ago
LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 2:30 p.m. Greenwich Mean Time (9:30 a.m.
Positive
Seeking Alpha
about one month ago
Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis, driving recurring revenue and strong growth. Q3 FY2025 ARCALYST revenue was $180.9M (+61% YoY, +15% QoQ), prompting raised FY2025 guidance to $670–$675M. ARCALYST's efficacy and new ACC guidance support increased patient-months, leading to a more steady revenue stream and repo...
Neutral
Seeking Alpha
about one month ago
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Jonathan Kirshenbaum - Investor Relations Officer Sanj Patel - CEO & Chairman of the Board Ross Moat - Executive VP & Chief Commercial Officer Mark Ragosa - Senior VP & CFO John Paolini - Executive VP & Chief Medical Officer Conference Call Participants Mary Kate Dav...
More Kiniksa Pharmaceuticals Ltd. Class A News

Company Profile

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

Head office Bermuda
CEO Sanj Patel
Employees 315
Founded 2015
Website www.kiniksa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today